Ifp Advisors, Inc Catalyst Pharmaceuticals, Inc. Transaction History
Ifp Advisors, Inc
- $3.07 Billion
- Q1 2025
A detailed history of Ifp Advisors, Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 23 shares of CPRX stock, worth $517. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23
Previous 23
-0.0%
Holding current value
$517
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$420 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$191 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$124 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$76.9 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$70.5 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.31B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...